Sana Biotechnology is a clinical-stage biotechnology company focused on developing engineered cells as medicines to treat diseases. The company was founded in 2018 by Flagship Pioneering and is based in Seattle, Washington. Sana's platform aims to create and deliver engineered cells that can replace, repair, or enhance tissue and organ function.
The company raised over $700 million in its Series A and B funding rounds before going public on NASDAQ in February 2021 under the ticker SANA. Sana's approach includes developing allogeneic cell therapies, including CAR-T cells and other engineered immune cells, as well as regenerative medicine applications. The company has been advancing multiple programs through preclinical and early clinical development, targeting oncology and other therapeutic areas where cell-based therapies could provide transformative treatment options.
Sana Biotechnology has received investment from 3 venture capital firms.
Clinical-stage biotech developing engineered cells as medicines to treat diseases through cell therapy platforms.
Sana Biotechnology has received investment from Andreessen Horowitz Bio + Health, Flagship Pioneering, Section 32. These venture capital firms and investors provide both capital and strategic support.
Sana Biotechnology operates in the Biotech sector. Clinical-stage biotech developing engineered cells as medicines to treat diseases through cell therapy platforms.
